Neurology Segment, by Application to Account Largest Share in Embolization Devices Market during 2025-2031

According to our new research study on "Embolization Devices Market Forecast to 2031 - Global Analysis - by Product Type, Application, and End User, and Geography," the market was valued at US$ 33.07 billion in 2024 and is projected to reach US$ 5.89 billion by 2031; it is expected to register a CAGR of 9.9% from 2025 to 2031. The embolization devices market growth is attributed to the rising prevalence of clinical conditions and burgeoning demand for minimally invasive techniques.

Embolization is a minimally invasive method used to block blood flow to targeted areas, such as tumors or abnormal blood vessels, by introducing embolic agents via catheters. This method has found wide application in treating AVMs, aneurysms, and certain types of cancer. The preference for such techniques has been on the rise due to their benefits over traditional surgical procedures, including reduced hospital stays, lower complication rates, and faster recovery times.

In uterine fibroid treatment, uterine artery embolization offers an alternative to the conventional treatment approach, such as hysterectomy. A study published in the Journal of Vascular and Interventional Radiology noted that uterine artery embolization had success rates of over 90%, significantly reducing symptoms while preserving the functioning of the uterus, which is particularly appealing among women of reproductive age. Additionally, older individuals often have comorbidities that make them poor candidates for traditional surgical procedures, thus increasing the demand for minimally invasive options. For instance, transarterial chemoembolization (TACE) has become a widely adopted first-line therapy in treating hepatocellular carcinoma (HCC), a common liver cancer in elderly patients. The use of microspheres and drug-eluting beads in TACE helps enhance the HCC treatment. In addition to blocking blood supply, these advanced embolic agents effectively deliver localized chemotherapy to the tumor, improving therapeutic efficacy while reducing systemic side effects. The National Cancer Institute reports that TACE can extend median survival in intermediate-stage HCC patients to 20 months, offering a safer alternative to surgical resection.

Bioresorbable embolic materials have emerged as another development in the embolic devices market; these materials offer temporary occlusion and are gradually absorbed by the body, reducing long-term complications and enabling future treatment options. As healthcare systems worldwide shift toward minimally invasive and cost-effective interventions, patients and clinicians increasingly prioritize treatment options that minimize trauma, recovery time, and complications. Thus, embolization provides a minimally invasive alternative to traditional surgeries, offering targeted treatment, symptom relief, and enhanced quality of life for patients. These benefits are driving the adoption of embolization devices in clinical practice.

Based on product, the embolization devices market is segmented into embolization coils, plugs, beads, glues, and others. The embolization coils segment held a larger embolization devices market share in 2024, and the segment is expected to register a higher CAGR during 2025-2031. Embolization coils are used in interventional procedures to block the blood flow in blood vessels. There are two types of embolization coils: detachable and pushable. Detachable embolization coils are used for the venous and arterial embolization in the peripheral vasculature. The coils are available in several rigidity, size, and shape specifications, and catheter compatibilities, among others, which render them suitable for various functions. The coils, generally made up of platinum, are placed with one-click mechanical detachment handle technology. Detachable coils are most useful for intracranial interventions or in conditions with an elevated risk of coil migration due to high vascular flow; they can be recaptured and repositioned several times before release, allowing more precise placement. Some detachable coils are released when a weld is split under pressure or electrolytically. For instance, in GDC Detachable Coils (Cook Medical) and Matrix Detachable Coils (Boston Scientific), the connection between the coil and the delivery wire dissolves when the operator applies a current to the delivery wire. Hydrogel coils are available as detachable coils. The Concerto Helix and 3D Detachable Coil Systems (Medtronic) offer helical and complex options for peripheral embolization, in diameters ranging from 2 mm to 20 mm.

Pushable coils are widely used for the mechanical occlusion of peripheral and visceral vessels. These coils are readily available, cost-effective, user-friendly, quickly deployed, and easy to use, which are perceived as their key advantages. Pushable coils are a standard, cost-effective, and time-saving tool for indications that require embolic agents. Hydrogel-coated pushable coils-e.g., AZUR Pushable 35 and 18 by Terumo Medical Corporation-benefit through increased filling capacity regardless of thrombus formation. Further, VortX Coils by Boston Scientific Corporation provide compact, complete vascular occlusion and efficient embolization. Embolic coils are used in the treatment of renal cancer, hepatocellular carcinoma, neuroendocrine tumors, aortic artery disorders, and peripheral vascular diseases.

Based on application, the market is segmented into neurology, peripheral vascular disease, oncology, urology, and others. The neurology segment held the largest embolization devices market share in 2024, and the same segment is estimated to register the higher CAGR during 2025-2031. Embolization devices have become essential tools in modern interventional neuroradiology and endovascular neurosurgery, offering a minimally invasive approach to treat complex cerebrovascular disorders. These devices are engineered to occlude or reduce blood flow to specific areas of the central nervous system (CNS), primarily targeting abnormal or compromised vessels in the brain and spinal cord. Highly vascular tumors such as meningiomas can be embolized preoperatively using particles or liquid agents, significantly reducing intraoperative bleeding and surgical time.

Based on end user, the market is segmented into hospitals, ambulatory centers and others. The hospital segment held the largest embolization devices market share in 2024, and the same segment is estimated to register the highest CAGR during 2025-2031. Hospitals remain the dominant end users of embolization devices due to their comprehensive infrastructure, access to advanced diagnostic systems, and availability of multidisciplinary care teams. These facilities are equipped to perform complex embolization procedures for the treatment of cerebral aneurysms and trauma-related hemorrhages, and to carry out preoperative tumor devascularization. The market growth of the hospital segment is fueled by the rising incidence of vascular diseases, cancers, and traumatic injuries, all of which frequently require hospital-based interventions. In addition, the increasing number of hybrid operating rooms and integration of image-guided therapy within hospital systems favor the adoption of embolization procedures. Academic and research hospitals also contribute to market growth by incorporating embolization into clinical trials and medical education. Further, hospitals benefit from strong partnerships with medical device companies, enabling them to be early adopters of newer, more sophisticated embolization materials and delivery systems. Government and private funding for stroke centers and trauma care units is another driving force, as embolization is a key component of care provided in these facilities. As global healthcare systems shift toward minimally invasive therapies to reduce recovery time and improve outcomes, hospitals are investing more in interventional radiology, further bolstering their role in the growth of the embolization device market.

Medtronic Plc, Cook Medical Holdings LLC, Stryker Corp, Boston Scientific Corp, Terumo Corp, Johnson & Johnson, Abbott Laboratories, NeuroSafe Medical Co. Ltd, Wallaby Medical, Sirtex Medical Ltd, GEM srl, Balt, Lepu Medical Technology Beijing Co Ltd, INVAMED, Meril Life Sciences Pvt Ltd, Merit Medical Systems Inc, and Lifetech Scientific Corp are among the leading companies operating in the global embolization devices market.

Companies operating in the embolization devices market adopt various organic and inorganic strategies. Organic strategies mainly include product launches and product approvals. Acquisitions, collaborations, and partnerships are among the inorganic growth strategies witnessed in the embolization devices market. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall embolization devices market growth. Further, acquisition and partnership strategies help them strengthen their customer base and expand their product portfolios.

Contact Us
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com